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aTATE-OF-THE-ART PAPER1169Estimating Cardiovascular Risk in Asymptomatic Subjectseffrey S. Berger, Courtney O. Jordan, Donald Lloyd-Jones, Roger S. Blumenthal
isk-stratifying asymptomatic patients for cardiovascular disease remains challenging, particularly
or those with low or intermediate short-term risk. Berger and colleagues review 6 of the
urrently available risk algorithms including the end points, the population in which it was
erived and/or validated, the variables included, and the limitations. Several areas of
ncertainty remain including the utility of 10-year versus lifetime risk, whether it is more
seful to try to predict cardiovascular disease or coronary heart disease end points, and the age
t which to start assessments. The conclusion is that the best approach is to routinely perform
risk score assessment with each patient, including discussion of the global cardiovascular risknd lifetime risk.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY1178Stent Overlap Linked to Worse Outcomesorenz Räber, Peter Jüni, Lukas Löffel, Simon Wandel, Stéphane Cook, Peter Wenaweser, Mario Togni,
olf Vogel, Christian Seiler, Franz Eberli, Thomas Lüscher, Bernhard Meier, Stephan Windecker
äber and colleagues compared the angiographic and long-term clinical outcome between
atients with and without overlap of drug-eluting stents (DES). Over 1,000 subjects enrolled
n the SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary
evascularization) trial were divided according to the presence or absence of stent overlap and
umber of stents per vessel: 13% had multiple DES in a vessel with overlap, 20% had
ultiple DES in a vessel without overlap, and the remaining 67% had a single DES per
essel. Angiographic follow-up showed an increased late loss in DES overlap patients
ompared with the other groups and the smallest mean luminal diameter was located at the
one of stent overlap. Major adverse cardiac events were more common in patients with
verlap. DES overlap appears to be frequent and may be associated with impaired
ngiographic and long-term clinical outcome.(continued on page A-20)
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EYOCARDIAL INFARCTION1189Ranolazine May Be Beneficial in ACS Patients With Elevated BNP0
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27090
Days from Randomizationavid A. Morrow, Benjamin M. Scirica, Marc S. Sabatine, James A. de Lemos, Sabina A. Murphy,
etr Jarolim, Pierre Theroux, Christophe Bode, Eugene Braunwald
ecause ranolazine is believed to reduce ventricular wall stress, B-type natriuretic peptide
BNP), which rises in response to wall stress, may identify those patients most likely to
enefit from treatment. Morrow and colleagues tested this hypothesis with samples collected
rom the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in
on–ST Elevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) trial which
andomized subjects with acute coronary syndromes (ACS) to either ranolazine or placebo.
ubjects with BNP 80 pg/ml were at significantly higher risk of the primary end point at
year. In these patients, ranolazine reduced the primary end point (hazard ratio: 0.79), while
here was no detectable effect in those with BNP 80 pg/ml. These findings indicate that
anolazine may be beneficial in high-risk patients with ACS identified by elevated BNP.ditorial Comment: : Steven P. Marso, p. 1197YOCARDIAL INFARCTION1200Cyclosporine Prior to Angioplasty May Safely Reduce Infarct Sizeathan Mewton, Pierre Croisille, Gerald Gahide, Gilles Rioufol, Eric Bonnefoy, Ingrid Sanchez,
hien Tri Cung, Catherine Sportouch, Denis Angoulvant, Gérard Finet, Xavier André-Fouët,
eneviève Derumeaux, Christophe Piot, Hélène Vernhet, Didier Revel, Michel Ovize
he rationale for this proof-of-concept study was that cyclosporine is a potent inhibitor of the
pening of the mitochondrial permeability transition pore, which plays a crucial role in
eperfusion injury. Mewton and colleagues randomized 28 patients with acute myocardial
nfarction to receive a single dose of cyclosporine or placebo at the time of reperfusion.
ardiac magnetic resonance imaging was performed 5 days and 6 months later. Infarct size
as reduced at 6 months in the cyclosporine group compared with the control group. This
as associated with a significant reduction of left ventricular end-systolic volume both at day
and at 6 months after infarction. There was no evidence of an effect on remote,
oninfarcted myocardium. These early results suggest that cyclosporine, injected prior to
eperfusion, can reduce infarct size without detrimental cardiac effects.
ditorial Comment: : Nathaniel Reichek, Kambiz Parcham-Azad, p. 1206(continued on page A-22)
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EIPID DISORDERS1209Atorvastatin Decreases Insulin Sensitivitywang Kon Koh, Michael J. Quon, Seung Hwan Han, Yonghee Lee, Soo Jin Kim, Eak Kyun Shin
linical trials suggest that some statin treatments may increase the incidence of diabetes. Koh and
olleagues investigated whether atorvastatin decreases insulin sensitivity and increases ambient
lycemia in hypercholesterolemic patients by randomizing subjects to varying doses of atorvastatin
r placebo for 2 months. Atorvastatin significantly increased fasting plasma insulin and glycated
emoglobin levels and decreased insulin sensitivity. Atorvastatin treatment, despite lowering low-
ensity lipoprotein cholesterol, may cause insulin resistance in hypercholesterolemic patients.EART RHYTHM DISORDERS1217Immediate Changes Seen in Atrial EP Properties After Mitral Commissurotomyobby John, Martin K. Stiles, Pawel Kuklik, Anthony G. Brooks, Sunil T. Chandy, Jonathan M. Kalman,
rashanthan Sanders
ohn and colleagues studied the effect of chronic stretch on the electrophysiological (EP)
haracteristics of the atria. Subjects with mitral stenosis undergoing mitral commissurotomy
MC) underwent detailed EP studies of the right and left atria before and after the
rocedure. Immediately after MC, there was a significant decrease in left atrial volume and
ressure. This was associated with a reduction in P-wave duration, and increases in
onduction velocity and voltage. The electrophysiologic and electroanatomic abnormalities
hat result from chronic atrial stretch and seem to predispose to atrial fibrillation, may resolve
lmost immediately when the atrial pressure is reduced.ADIATION INJURY1227Prolonged NF-B Activation May Underlie Radiation Induced Cardiac Eventsartin Halle, Anders Gabrielsen, Gabrielle Paulsson-Berne, Caroline Gahm, Hanna Agardh,
ilip Farnebo, Per Tornvall
ecent studies have shown that radiotherapy is associated with cardiovascular disease years
fter treatment. Halle and colleagues investigated gene expression networks in previously
adiated human arteries and compared them to arteries from a nonradiated site in subjects
ndergoing cancer reconstruction surgery, 4 to 500 weeks after radiation treatment. The
rterial biopsies were compared, using Affymetrix (Santa Clara, California) microarrays.
hirteen genes were synchronously expressed in all radiated segments at levels higher or lower
han nonradiated segments. Most of the differentially regulated genes related to the nuclear
actor-kappa B (NF-B) signaling pathway. NF-B activation was confirmed by
mmunohistochemistry and immunofluorescence. The observed sustained inflammatory
esponse may be provoked by deoxyribonucleic acid injury and may explain cardiovascular
isease years after radiation.ditorial Comment: : Neal L. Weintraub, W. Keith Jones, David Manka, p. 1237
(continued on page A-24)
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1240olecular Imaging Shows Minocycline
Inhibits MMP Activity in Atherosclerotic Plaquesatoru Ohshima, Shinichiro Fujimoto, Artiom Petrov, Hironori Nakagami, Nezam Haider, Jun Zhou,
obuhiro Tahara, Mariana Kiomy Osako, Ai Fujimoto, Jie Zhu, Toyoaki Murohara, D. Scott Edwards,
avneet Narula, Nathan D. Wong, Y. Chandrashekhar, Ryuichi Morishita, Jagat Narula
atrix metalloproteinase (MMP) activity may contribute to plaque instability and is a
otential therapeutic target for plaque stabilization. Ohshima and colleagues used a broad
pectrum matrix metalloproteinase inhibitor (MPI) labeled with technetium to noninvasively
uantify MMP activity in atherosclerotic plaques, and the effect of treatment with fluvastatin
FS) and minocycline (MC) on MMP activity. Atherosclerotic lesions were produced in
abbits who were then treated with either FS, low-dose MC, high-dose MC, a combination
f MC and FS, or no intervention for 4 months. MPI uptake was highest in the control
nimals and was significantly lower in each of the active treatment groups. Histological
nalysis confirmed the visualized findings. This imaging technique may be a useful surrogate
or studying the efficacy of MMP-targeted interventions.RE-CLINICAL RESEARCH
1250xtracellular Matrix Isolated From the Pig Small Intestine
May Promote Post-MI Recoveryhi-Qing Zhao, John D. Puskas, Di Xu, Ning-Ping Wang, Mario Mosunjac, Robert A. Guyton,
akob Vinten-Johansen, Robert Matheny
his study tested the hypothesis that injecting small intestine extracellular matrix emulsion
EMU) directly into the myocardium would stimulate the recruitment of positive factors after
yocardial infarction. Sixty-four rats were subjected to 45 min of ischemia followed by
eperfusion; saline or EMU was directly injected into the area at risk myocardium after
eperfusion. The population of c-kit–positive cells, alpha-smooth muscle actin–
xpressing myofibroblasts and macrophages in the infarcted myocardium were all
ignificantly increased after EMU injection. Angiogenesis in the EMU area was also
nhanced and echocardiography showed significant improvements in the EMU group.
njection of EMU into the infarcted myocardium appears to increase neovascularization and
reserve cardiac function.(continued on page A-25)
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tEWS FROM THE NHLBI1262The NHLBI Bench to Bassinet Programonathan R. Kaltman, Charlene Schramm, Gail D. Pearson
o accelerate the discoveries that may lead to improved clinical outcomes for children with
ongenital heart disease (CHD), the National Heart, Lung, and Blood Institute has launched
novel translational research program, the Bench to Bassinet program. Kaltman and
olleagues describe the Bench to Bassinet program in this report. It is composed of 3 entities.
he Cardiovascular Development Consortium, which will attempt to elucidate the regulatory
nd developmental derangements that cause CHD. The Pediatric Cardiac Genomics
onsortium’s goals are to delineate the genetic underpinnings of CHD through genome-wide
nalytic techniques and high-throughput sequencing. These new programs will interact with
he Pediatric Heart Network and its existing clinical trials/research infrastructure, to rapidly
ranslate any promising findings to the clinical world.EXPEDITED PUBLICATION XPEDITED PUBLICATION1266Rosuvastatin Effective in JUPITER Trial Patients With CKD0 1 2 3 4
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Primary Endpoint + All Death aul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn
ndividuals with moderate chronic kidney disease (CKD) are at an increased risk of
yocardial infarction, stroke, and vascular death, yet the efficacy of primary prevention with
tatins is controversial in this population. Ridker and colleagues performed a subset analysis of
he JUPITER (Justification for the Use of statins in Prevention–an Intervention Trial
valuating Rosuvastatin), dividing subjects by the presence or absence of moderate CKD,
efined as an estimated glomerular filtration rate 60 ml/min/1.73 m2. The JUPITER
articipants with CKD had higher vascular event rates (hazard ratio: 1.54) and a 45%
eduction in risk of myocardial infarction, stroke, hospitalization for unstable angina, arterial
evascularization, or confirmed cardiovascular death, and a 44% reduction in all-cause
ortality when randomized to rosuvastatin. Because of the higher event rates in those with
oderate CKD, the number needed to treat at 5 years was 14 for the primary end point, and
for the end point that also included total deaths and venous thromboembolism, comparedo 35 and 25, respectively, for those with more preserved renal function.
